[1] [1] WANG M, HERBST R S, BOSHOFF C. Toward personalized treatment approaches for non-small-cell lung cancer［J］ . Nature Medicine, 2021, 27(8): 1345-1356.

[2] [2] CARNEIRO B A, El-DEIRY W S. Targeting apoptosis in cancer therapy［J］ . Nature Reviews Clinical Oncology, 2020, 17(7): 395-417.

[3] [3] KASHYAP D, GARG V K, GOEL N. Intrinsic and extrinsic pathways of apoptosis: role in cancer development and prognosis［J］ . Advances in Protein Chemistry and Structural Biology, 2021, 125: 73-120.

[4] [4] XU M, LUJH, ZHONGYZ, et al. Immunogenic cell death-rele-vant damage-associated molecular patterns and sensing receptors in triple-negative breast cancer molecular subtypes and implica-tions for immunotherapy［J］ . Frontiers in Oncology, 2022, 12: 870914.

[5] [5] JIN M Z, WANG X P. Immunogenic cell death-based cancer vac-cines［J］ . Frontiers in Immunology, 2021, 12: 697964.

[6] [6] BAO X, XIE L. Targeting purinergic pathway to enhance radio-therapy-induced immunogenic cancer cell death［J］ . Journal of Experimental & Clinical Cancer Research, 2022, 41(1): 222.

[7] [7] RADOGNA F, DICATO M, DIEDERICH M. Natural modulators of the hallmarks of immunogenic cell death［J］ . Biochemical Pharmacology, 2019, 162: 55-70.

[8] [8] SACHLOS E, RISUENO R M, LARONDE S, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells［J］ . Cell, 2012, 149(6): 1284-1297.

[9] [9] WANG Y, XIA L, LIN J, et al. Thioridazine combined with car-boplatin results in synergistic inhibition of triple negative breast cancer by targeting cancer stem cells［J］ . Translational Oncology, 2022, 26: 101549.

[10] [10] KANG S, DONG S M, KIM B R, et al. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervi-cal and endometrial cancer cells［J］ . Apoptosis, 2012, 17(9): 989-997.

[11] [11] CHU C W, KO H J, CHOU C H, et al. Thioridazine enhances p62-mediated autophagy and apoptosis through wnt/β-catenin signaling pathway in glioma cells［J］ . International Journal of Molecular Sciences, 2019, 20(3): 473.

[12] [12] FUCIKOVA J, SPISEK R, KROEMER G, et al. Calreticulin and cancer［J］ . Cell Research, 2021, 31(1): 5-16.

[13] [13] FAN F, SHEN P, MA Y, et al. Bullatacin triggers immunogenic cell death of colon cancer cells by activating endoplasmic reticu-lum chaperones［J］ . Journal of Inflammation (London, England), 2021, 18(1): 23.

[14] [14] WEST H, MCCLEOD M, HUSSEIN M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for met-astatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial［J］ . The Lan-cet Oncology, 2019, 20(7): 924-937.

[15] [15] BRUECKL W M, FICKER J H, ZEITER G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibi-tor (ICI) therapy in non-small cell lung cancer (NSCLC)［J］ . BMC Cancer, 2020, 20(1): 1185.

[16] [16] KULBAY M, PAIMBOEUF A, OZDEMIR D, et al. Review of cancer cell resistance mechanisms to apoptosis and actual targeted therapies［J］ . Journal of Cellular Biochemistry, 2022, 123(11): 1736-1761.

[17] [17] LI X, WANG J, GONG X, et al. Upregulation of Bcl-2 by acri-done derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH［J］ . Nucleic Acids Research, 2020, 48(15): 8255-8268.

[18] [18] ZHAO S, ZHANG Y, LU X, et al. CDC20 regulates the cell pro-liferation and radiosensitivity of p53 mutant HCC cells through the Bcl-2/Bax pathway［J］ . International Journal of Biological Sciences, 2021, 17(13): 3608-3621.

[19] [19] LI X. The inducers of immunogenic cell death for tumor immuno-therapy［J］ . Tumori, 2018, 104(1): 1-8.

[20] [20] HUANG L, RONG Y, TANG X, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer［J］ . Molecular Cancer, 2022, 21(1): 45.

[21] [21] AHMED A, TAIT S. Targeting immunogenic cell death in cancer［J］ . Molecular Oncology, 2020, 14(12): 2994-3006.